Clinical Trial: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU

U.S., April 28 -- ClinicalTrials.gov registry received information related to the study (NCT07552012) titled 'A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU' on March 11.

Brief Summary: The purpose of this study is to find out the efficacy and safety of oral FXS5626 in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

Study Start Date: Jan. 29

Study Type: INTERVENTIONAL

Condition: Active Non-anterior, Non-infectious Uveitis

Intervention: OTHER: FXS5626 tablet

Administered twice per day for 24 weeks.

OTHER: FXS5626 tablet

Administered twice per day for 24 weeks.

OTHER: Placebo

Administered twice per day for 24 weeks.

Recruitment S...